On 6-8 November 2024, Professor Aisling McMahon, School and Law of Criminology, attended and spoke at the ‘Cell 2024’ conference in London. This international three-day conference brought together leading clinical, academic and industry speakers to discuss cutting-edge issues in the cell and gene therapy space. Professor McMahon took part in two conference sessions.
On 6 November, Prof McMahon was invited to participate on a panel which focused on ‘Cell and Gene Therapies: Intellectual Property Challenges’. She spoke alongside other panelists: Dr Anton Hutter, Partner, Patent Attorney, Venner Shipley; Dr Lucy Williams, Partner, European and UK Patent Attorney, J A Kemp; and Dr Matthew Garner, Head of Intellectual Property, Cell and Gene Catapult. This panel was chaired by Dr Eli Gilsohn, Vice President Intellectual Property, Resolution Therapeutics. The panel featured discussions on the current landscape, challenges, and broader policy considerations around intellectual property protections in the cell and gene therapy context.
On 8 November, Prof McMahon delivered a presentation entitled “Delivering Sustainable Pathways for the Provision Of CAR-T Therapies to Patients: Legal, Ethical, and Regulatory Challenges & Opportunities” at the conference. This presentation considered the legal, ethical, and regulatory considerations around delivering sustainable patient centred pathways for the provision of CAR-T therapies within public health contexts. This drew on research developed as part of an IRC New Foundations funded project on ‘Access and Provision of CAR-T therapies’ .
Prof McMahon’s research focuses on the regulation of emerging health-technologies, and the role/impact of IPRs on development, delivery and access to emerging health-technologies. She is the Principal Investigator of the ERC funded PatentsInHumans project. You can find out more about her research here.